TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic ischemic heart failure caused by a heart attack~* Scheduled to undergo cardiac surgery for CABG~* Ejection fraction between 15% and 50%~* Presence of an akinetic or dyskinetic region by standard imaging~Exclusion Criteria:~* Glomerular filtration rate of less than 50 mL/min/1.73m2 at study entry~* Contraindication to performance of an MRI scan~* Bone marrow dysfunction, as evidenced by a 20% or more deviation from normal hematocrit, white blood cell count, or platelet values without another explanation~* A coagulopathy condition not due to a reversible cause (i.e., Coumadin)~* Known, serious radiographic contrast allergy~* Known allergies to penicillin or streptomycin~* Organ transplant recipient~* Clinical history of malignancy within 5 years of study entry (e.g., patients with prior malignancy must be disease free for 5 years), except curatively treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma~* Non-cardiac condition that limits lifespan to less than 1 year~* On chronic therapy with immunosuppressant medication~* Serum positive for HIV, hepatitis B, or hepatitis C~* Female who is pregnant, nursing, or of child-bearing potential and not practicing effective birth control methods

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lower dose mesenchymal stem cell (MSC) injection (Type: EXPERIMENTAL): Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10\^7 cells
- Higher dose MSC injection (Type: EXPERIMENTAL): Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10\^8 cells
- (3) Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Eligibility~* Age 18 years or older~* Patients who are clinically suspected of having elevated pulmonary blood pressure , due to cardiac or cardio-pulmonary disease preferably any one or more of the conditions listed below, and due to have right heart catheterization as part of the diagnostic work-up:~* Patients with CHF~* Patients with primary pulmonary arterial hypertension~* Patients with COPD~* Patients with asthma~* Patients with interstitial lung disease~* Patients with sarcoidosis~* Signed informed consent.~Exclusion Criteria:~* Patients unable to cooperate.~* Inability to assume a sitting or supine position~* Patients with severe chest wall deformity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exercise for Improving Prostate Oxygenation in Prostate Tumors (Exipox)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed PC~* planned radical prostatectomy~* informed consent given~* above 18 years of age~* BMI \< 30~* non-smoker~* living in Tromso region~Exclusion Criteria:~* Contraindications to the intervention like;~  * heart failure,~ * angina pectoris,~ * respiratory disease limiting possible intervention~ * use of physical supportive devices to aid movement~* High level of physical activity~* smoking~* BMI\>30

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Physical aerobic intervention (Type: EXPERIMENTAL): The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).
- Controls (Type: NO_INTERVENTION): These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Patients must have cytologic or histologic proof of adenocarcinoma of the pancreas.~All patients must be staged with a physical exam and CXR. Patients must have locally advanced disease defined as tumor extension to the celiac axis or SMA, or occlusion of the SMPV confluence (on contrast-enhanced CT). There must be no radiographic evidence of metastatic disease.~Patients must have had no prior chemotherapy or irradiation.~Patients must have a baseline Karnofsky performance status of at least 60.~Patients must have adequate bone marrow reserve platelet count \>100,000/mL, hemoglobin\>9 g/dL, absolute granulocyte count must be \>1,500 cells/mm3,serum creatinine must be \<1.6 mg/dL. Serum bilirubin must be less than 5 mg/dL prior to therapy with endoscopic or percutaneous drainage if necessary.~Patients must have estimated life expectancy of at least 12 weeks.~Patients must be at least 18 years of age. There will be no upper age restriction.~Female patients must have had childbearing potential terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device \[IUD\], birth control pills, barrier device, or abstinence.~Patients cannot have hepatic or peritoneal metastases detected by ultrasound (US), CT scan, or laparotomy prior to chemoradiation.~Before receiving external beam irradiation, patients should be able to maintain adequate oral nutrition (90% to 100% of estimated need of calories and protein) and be free of significant nausea and vomiting.~Patients should have bilateral renal function, as determined on excretory urogram (IVP) or abdominal CT, or \>2/3 of one functioning kidney must be able to be shielded from the radiation beam.~Patients must have no fever or evidence of infection or other coexisting medical condition that would preclude protocol therapy.~Patients must sign an informed consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemzar Chemoradiation + TNP-470 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ataxia in Essential Tremor: Describing the Differences Between Disease Process and Treatment Effect

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Essential Tremor diagnosis at least 3 years duration~* Absence of other neurological signes (such as dystonia, ataxia, or Parkinsonism)~* Patients must be able to walk 2 minutes unassisted.~* Patients must be able to understand and consent to be in the study.~Exclusion Criteria:~* Patients who have had changes in DBS settings within the last 3 months.~* Patients who have had no initial improvement or response to DBS.~* ET medication changes in the last month.~* Actively abusing alcohol.~* A neurologic diagnosis other than ET that in the investigator's opinion could affect gait and/or balance.~* Atypical tremor disorder including by not limited to tremor due to multiple sclerosis, medication-induced tremor, Parkinson's disease, or parkinsonian syndrome.~* Dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ET (DBS-, Ataxia+) (Type: None): Essential Tremor without DBS with Ataxia on examination
- ET (DBS-, Ataxia-) (Type: None): Essential Tremor without DBS and without Ataxia on examination
- ET (DBS+, Ataxia+) (Type: None): Essential Tremor with DBS with Ataxia on examination
- ET (DBS+, Ataxia-) (Type: None): Essential Tremor with DBS without Ataxia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven malignant melanoma at primary or any metastatic site Bidimensionally measurable disease by MRI scan Must have 1-6 enhancing brain metastases If at least 2 lesions are present, only 1 lesion may be greater than 3 cm in maximum diameter~PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic response modifier or immunotherapy Chemotherapy: No concurrent chemotherapy with whole brain radiotherapy Prior systemic chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: No prior stereotactic or conventional radiotherapy to any field of the brain Surgery: Prior surgical resection of brain metastases allowed (provided 1 or 2 measurable brain metastases remain)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the VEGA Knee System® Range of Motion

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* willing to sign the informed consent.~* Patient has intact collateral ligaments.~Exclusion Criteria:~* Inflammatory arthritis~* Patients that have had a high tibial osteotomy or femoral osteotomy~* Patients with neuromuscular or neurosensory deficiency which would make it difficult to assess the device performance.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predict Near Future Initiation of Bed Exit

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion:~1. Ambulatory patient able to leave the bed.~2. Willingness to consent and participate in a 30-night study~Exclusion:~1. Lack of capacity to consent, without an identifiable surrogate.~2. Terminal Prognosis~3. Unstable health, as determined by the principal investigator, medical doctor, or registered nurse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bed Exit (Type: None): Participants will be up to 60 ambulatory Budd Terrace residents.~Inclusion/Exclusion:~Inclusion:~1. Ambulatory patient able to leave the bed.~2. Willingness to consent and participate in a 30-night study~Exclusion:~1. Lack of capacity to consent, without an identifiable surrogate.~2. Terminal Prognosis~3. Unstable health, as determined by the principal investigator, medical doctor, or registered nurse.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject at least 18 years of age~* Diagnosis of psoriasis, with palmoplantar involvement~* Initiated on oral acitretin for treatment of their psoriasis by their physician~Exclusion Criteria:~* Subjects less than 18 years old~* Subjects with any skin disease, disease state, or physical condition that would impair evaluation of the skin~* Additional systemic therapy for psoriasis in last 4 weeks~* Additional topical or photo-therapy in last 2 weeks~* Usage of any additional therapy except for emollients and keratolytic agents (5% salicylic acid ointment or 30% urea cream)~* Pre-existent or current cutaneous malignancy affecting the palms and/or soles~* History of photosensitive disorders~* Ingestion of drugs reported to cause photosensitivity reactions~* Presence of erythroderma or generalized pustular psoriasis~* Concomitant use of sunlamps

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- First Group (Type: EXPERIMENTAL): excimer laser treatment to one palm and/or one sole
- Second Group (Type: EXPERIMENTAL): excimer laser treatment to both palms and/or soles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Flaxseed in NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, ages 18 and older~* Current diagnosis of non-small cell lung cancer (NSCLC) including patients who have metastatic disease requiring definitive thoracic and mediastinal radiotherapy with concurrent chemotherapy.~* Able to provide written informed consent and comply with all study procedures~* Total planned radiation dose to gross disease 60-70 Gy.~Exclusion Criteria:~* Current diagnosis of disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication (history of major gastrointestinal tract surgery, gastrectomy, gastrostomy, bowel resection, etc.) or history of chronic gastrointestinal disorders (ulcerative colitis, regional enteritis, or gastrointestinal bleeding)~* Known hypersensitivity to flaxseed or any of its metabolites, or wheat products~* Taking or has taken an investigational drug within 14 days.~* Taking or has taken Amifostine or Mucomyst (N-acetylcysteine) within 14 days~* Current or prior use of flaxseed, flax-containing products, soybeans, or soy-containing products~* Current or prior use (limited to prior 14 days) of dietary supplements such as herbals or botanicals~* Prior thoracic and/or mediastinal radiation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dietary Supplement: Flaxseed (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pain and Schizophrenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with schizophrenia (criteria DSM IV) or healthy controls matched with patients on age, sex and education level~* 18-55 years old~Exclusion Criteria:~* Past history affecting CNS~* Intake of psychotropic drugs, except for patients~* Metabolic disorder affecting sensory processing (diabetes)~* Intake of benzodiazepines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Patients with schizophrenia (Type: EXPERIMENTAL): None
- Healthy controls (Type: ACTIVE_COMPARATOR): controls matched with patients on age, sex and education level

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Low Anterior Resection Syndrome by Percutaneous Nerve Evaluation and Transanal Irrigation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Low anterior resection for rectal cancer between May 2001 and May 2011~Exclusion Criteria:~* Non-radical resection~* metastatic disease~* Chemotherapy~* Radiotherapy~* Previously treated for another cancer~* Dementia or other mental retardation/severe mental disease~* Inability to read and understand the Danish language~* Recurrent disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PNE first (Type: ACTIVE_COMPARATOR): patients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
- TAI first (Type: ACTIVE_COMPARATOR): Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures~* Medical indication for the treatment with a PCSK9-inhibitor~* HbA1c \< 6,5%~Exclusion Criteria:~* Diabetes mellitus~* Pregnant women or breastfeeding~* Hb \< 11.5 g/dl (males) or Hb \< 10.5 g/dl (females)~* treatment with any medication that effects on blood glucose concentrations, e.g. antidiabetic drugs or steroids~* Any pancreatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LDL lowering therapy (Type: EXPERIMENTAL): Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Fecal Immunochemical Test Using Digital Rectal Exam

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults between the ages of 50-75 who are due for colon cancer screening and scheduled for colonoscopy~* Preoperative patients with established diagnosis of colon cancer~Exclusion Criteria:~* Patients with a diagnosis of Inflammatory Bowel Disease (IBD).~* Patients who are pregnant.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- FIT-SOC (Type: ACTIVE_COMPARATOR): Fecal immunochemical test performed on spontaneously passed stool as noted in the standard instructions.
- FIT-DRE (Type: EXPERIMENTAL): Fecal immunochemical test completed with stool collected during digital rectal exam.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues